In Vitro Activity of TD-6424 against Staphylococcus aureus

John L. Pace, Kevin Krause, Deborah Johnston, Dmitri Debabov, Terry Wu, Lesley Farrington, Cassie Lane, Deborah L. Higgins, Burt Christensen, J. Kevin Judice,† and Koné Kaniga*

Theravance, Inc., South San Francisco, California 94080

Received 30 May 2003/Returned for modification 21 July 2003/Accepted 25 August 2003

TD-6424, a rapidly bactericidal agent with multiple mechanisms of action, is more potent in vitro and more rapidly bactericidal than currently available agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. TD-6424 produces a postantibiotic effect with a duration of 4 to 6 h against these organisms. The results suggest potential efficacy against susceptible and resistant strains of S. aureus.

Drug-resistant Staphylococcus aureus has become an increasingly important problem for the management of serious infections (2, 3, 6). TD-6424 is a new agent which is rapidly bactericidal for gram-positive bacteria. Its activity is mediated via a pair of biochemically distinct mechanisms. In addition to inhibition of peptidoglycan synthesis, TD-6424 also inhibits the synthesis of phospholipids required for integrity of the bacterial cell membrane (J. L. Pace, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. 454, p. 614, 2002). In the present study, the susceptibilities of methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), and glycopeptide-intermediate S. aureus (GISA) to TD-6424, vancomycin, oxacillin, linezolid, and teicoplanin were evaluated. The bactericidal activities and postantibiotic effects (PAEs) of TD-6424 and vancomycin against MSSA, MRSA, and GISA were also assessed.

S. aureus strains were clinical isolates obtained within the last 4 years from a variety of hospitals in the United States and Europe. Well-characterized S. aureus strains from the American Type Culture Collection (ATCC; Manassas, Va.), the Centers for Disease Control and Prevention (Atlanta, Ga.), and other sources were also used. TD-6424 was obtained from Theravance, and all other agents were obtained from Sigma-Aldrich (St. Louis, Mo.), the U.S. Pharmacopeia (Rockville, Md.), or Hoechst AG (now Aventis; Frankfurt am Main, Germany).

The MIC was determined by the broth microdilution method according to protocol M7-A5 of the NCCLS (5). The minimum bactericidal concentration (MBC) was determined according to protocol M26-A of the NCCLS (4) from the microtiter plates used to determine MICs with a starting inoculum of ~5 × 10^5 CFU/ml. After a 24-h incubation, the number of survivors from wells with no obvious turbidity was determined by plate counting of 100-μl samples. The MICs for TD-6424 and comparator antibiotics were determined by a time-kill assay (4) in 10 ml of Mueller-Hinton broth with a starting inoculum of ~10^6 CFU/ml of log-phase cultures. At regular intervals, bacteria were enumerated by plate counting from 200-μl samples. For both MBC and time-kill assays, bactericidal activity was defined as a ≥3-log10 decrease in the number of CFU per milliliter within 24 h. The limit of detection was 10 CFU/ml.

The durations of the PAEs were determined according to a published protocol (1) with the following modifications. In brief, the 20-ml starting inoculum of ~10^6 CFU/ml was exposed to the MIC of the compound for 1 h at 37°C. Bacteria were then removed from the antibiotic-containing medium by centrifugation and washed with saline to remove residual antibiotic. Bacteria were resuspended in 20 ml of prewarmed Mueller-Hinton broth and incubated with shaking. Plate counts were performed from 100-μl samples diluted appropriately at hourly intervals to determine the time at which a 1-log10 increase in CFU per milliliter occurred after antibiotic removal. The duration of PAE was calculated as the number of hours until return to log-phase growth of treated bacteria minus the time for return of control bacteria (no antibiotic but treated identically) to log-phase growth.

Susceptibility testing. TD-6424 was highly active against MSSA. The MICs of TD-6424 for these organisms were generally lower than those of vancomycin, oxacillin, linezolid, and teicoplanin (Table 1). The MICs of TD-6424 for 47 strains of MSSA ranged from 0.12 to 2 μg/ml, and the MIC at which 90% of organisms were inhibited (MIC90) was 1 μg/ml. The MIC of TD-6424 for ATCC 13709 was 0.06–2 μg/ml, compared to 0.5 μg/ml for nafcillin, gentamicin, and oxacillin, 1 μg/ml for vancomycin and teicoplanin, and 4 μg/ml for linezolid. TD-6424

<table>
<thead>
<tr>
<th>Organism</th>
<th>No. of strains</th>
<th>Antimicrobial agent</th>
<th>MIC (μg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Range</td>
</tr>
<tr>
<td>MRSA</td>
<td>128</td>
<td>TD-6424</td>
<td>≤0.06–2</td>
</tr>
<tr>
<td></td>
<td>128</td>
<td>Vancomycin</td>
<td>0.5–2</td>
</tr>
<tr>
<td></td>
<td>39</td>
<td>Teicoplanin</td>
<td>0.5–16</td>
</tr>
<tr>
<td></td>
<td>128</td>
<td>Linezolid</td>
<td>0.5–4</td>
</tr>
<tr>
<td></td>
<td>128</td>
<td>Oxacillin</td>
<td>4–&gt;64</td>
</tr>
<tr>
<td>MSSA</td>
<td>47</td>
<td>TD-6424</td>
<td>0.12–2</td>
</tr>
<tr>
<td></td>
<td>47</td>
<td>Vancomycin</td>
<td>0.5–2</td>
</tr>
<tr>
<td></td>
<td>38</td>
<td>Teicoplanin</td>
<td>0.5–2</td>
</tr>
<tr>
<td></td>
<td>47</td>
<td>Linezolid</td>
<td>2–4</td>
</tr>
<tr>
<td></td>
<td>47</td>
<td>Oxacillin</td>
<td>0.13–2</td>
</tr>
</tbody>
</table>

* Corresponding author. Mailing address: Theravance, Inc., 901 Gateway Blvd, South San Francisco, CA 94080. Phone: (650) 808-6158. Fax: (650) 808-6186. E-mail: kkaniga@theravance.com.
† Present address: Department of Medicinal Chemistry, Genentech, Inc., South San Francisco, CA 94080.
was more active against MRSA than were vancomycin, oxacillin, linezolid, and teicoplanin (Table 1). The MICs of TD-6424 for 128 strains of MRSA ranged from 0.06 to 2 μg/ml, and the MIC₉₀ was 1 μg/ml. The MIC of TD-6424 for ATCC 33591 was 0.5 μg/ml, compared to 1 μg/ml for vancomycin, 2 μg/ml for teicoplanin, linezolid, and gentamicin, and 128 μg/ml for nafcillin and oxacillin. TD-6424 (MIC 2 μg/ml) was more active than vancomycin, teicoplanin, nafcillin, and oxacillin (all MICs, 8 μg/ml) against GISA (HIP 5836).

**Bactericidal activity.** The MBCs of TD-6424 for MSSA (ATCC 13709), MRSA (ATCC 33591), and GISA (HIP 5836) were 2, 4, and 4 μg/ml, respectively; the corresponding values for vancomycin were 2, 4, and 8 μg/ml, and those for nafcillin were 0.5, 128, and 128 μg/ml. The results of time-kill assays demonstrated the rapid, concentration-dependent bactericidal activity of TD-6424. Results for MSSA indicated that TD-6424 (4 μg/ml) reduced the initial inoculum from log₁₀ 6.22 ± 0.08 CFU/ml to log₁₀ 3.36 ± 0.28 CFU/ml within 4 h after administration (Fig. 1A). Generally, similar results were obtained for nafcillin (4 μg/ml). With vancomycin (4 μg/ml), the initial inoculum was decreased by only about 1 log₁₀ at 4 h. Linezolid (8 μg/ml) exhibited the least bactericidal activity in this assay.

Results with TD-6424 for MRSA were generally similar to those for MSSA (Fig. 1B): TD-6424 at 8 and 32 μg/ml reduced the initial inoculum from log₁₀ 6.05 ± 0.08 CFU/ml to log₁₀ 4.87 ± 0.05 and 1.26 ± 0.26 CFU/ml, respectively, within 4 h. Vancomycin at 8 μg/ml exhibited much slower bactericidal activity, and linezolid at 16 μg/ml had almost no bactericidal activity against this organism. TD-6424 at 8, 16, and 32 μg/ml was also rapidly bactericidal against GISA (Fig. 1C). By 4 h, the 8- and 32-μg/ml concentrations had reduced the initial inoculum from log₁₀ 5.76 ± 0.07 to 3.21 ± 0.12 and 0.98 ± 0.02 CFU/ml, respectively. Linezolid at 8 μg/ml reduced the initial inoculum from log₁₀ 5.76 ± 0.07 CFU/ml to log₁₀ 2.73 ± 0.08 CFU/ml by 4 h, and vancomycin at 32 μg/ml decreased it from log₁₀ 5.76 ± 0.07 CFU/ml to log₁₀ 4.82 ± 0.02 CFU/ml over this period.

**PAE.** TD-6424 had long durations (≥4 h) of PAE against MSSA, MRSA, and GISA (Table 2). Vancomycin had substantially shorter PAEs, whereas nafcillin did not generate a PAE against the MSSA strain in this assay.

In summary, TD-6424 is highly active against MSSA, MRSA, and GISA and has significant bactericidal activity and a long PAE against these organisms. The in vitro properties of TD-6424 suggest that it may be effective in infections caused by both susceptible and resistant strains of *S. aureus*.

**TABLE 2. PAE for TD-6424 and comparator antibiotics**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>MSSA (ATCC 13709)</th>
<th>MRSA (ATCC 33591)</th>
<th>GISA (HIP 5836)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TD-6424</td>
<td>4</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Nafcillin</td>
<td>0</td>
<td>ND*</td>
<td>ND</td>
</tr>
</tbody>
</table>

* ND, not determined.
REFERENCES


